In short
Imifoplatin, also known as PT-112, is an innovative drug currently being studied in clinical trials for the treatment of advanced solid tumors, particularly metastatic castration-resistant prostate cancer (mCRPC). This article explores the ongoing research into Imifoplatin's safety, effectiveness, and potential benefits for patients with advanced prostate cancer who have undergone multiple prior treatments.
At a glance
- Drug Name
- Imifoplatin (PT-112)
- Trial Phase
- Phase 1, Open-Label
- Target Condition
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Administration
- Intravenous Infusion
- Dosing Schedule
- 250 mg/m² or 360 mg/m² on specific days of 28-day cycles
- Primary Objective
- Determine recommended dose and schedule for future studies
- Key Eligibility Criteria
- Men ≥18 years, confirmed mCRPC, ≥3 prior therapies, disease progression
- Main Endpoints
- Disease Control Rate at 4 months, Safety, Pharmacokinetics
What is IMIFOPLATIN?
IMIFOPLATIN, also known as PT-112, is a new drug being studied for the treatment of advanced prostate cancer. It belongs to a class of drugs called platinum-containing therapies, which are known for their potential in fighting cancer. IMIFOPLATIN is currently undergoing clinical trials to evaluate its safety and effectiveness in patients with advanced solid tumors, particularly those with metastatic castration-resistant prostate cancer (mCRPC).
Other names for IMIFOPLATIN include: (R,R)-1,2-CYCLOHEXANEDIAMINE PYROPHOSPHATOPLATINUM(II) PT-112 CYCLOHEXANE-(1R,2R)-DIAMINEPLATINUM(II) DIPHOSPHATE
Medical Condition Treated
IMIFOPLATIN is being studied specifically for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This is an advanced form of prostate cancer that: Has spread (metastasized) to other parts of the body beyond the prostate Continues to grow despite treatments that lower testosterone levels (castration)
This type of prostate cancer is particularly challenging to treat, as it has become resistant to standard hormone therapies.
How IMIFOPLATIN Works
While the exact mechanism of action for IMIFOPLATIN is not fully described in the provided information, as a platinum-containing therapy, it likely works by damaging the DNA of cancer cells, preventing them from dividing and ultimately leading to their death. This approach is similar to other platinum-based chemotherapy drugs, but IMIFOPLATIN may have unique properties that researchers hope will make it effective against resistant forms of prostate cancer.
Current Clinical Trial
IMIFOPLATIN is currently being studied in a Phase 1 clinical trial. The main objectives of this trial are: To determine the safe and effective dose of IMIFOPLATIN To evaluate how well patients tolerate the drug To assess how effective the drug is in controlling the disease
The trial is testing different dosing schedules to find the best balance between effectiveness and side effects. The primary measure of effectiveness is the disease control rate at 4 months (DCR4), which refers to the percentage of patients whose cancer does not worsen during this period.
Eligibility for the Trial
The trial is open to men aged 18 and older with confirmed metastatic castration-resistant prostate cancer. Some key eligibility criteria include: Having received at least three prior life-prolonging therapies for metastatic disease Having evidence of disease progression Being in generally good health with adequate organ function Not having certain other medical conditions that might interfere with the study
How IMIFOPLATIN is Administered
IMIFOPLATIN is given as an intravenous infusion, which means it's delivered directly into the bloodstream through a vein. The current trial is testing two main dosing schedules: 250 mg/m² on Days 1 and 15 of each 28-day cycle 360 mg/m² on Days 1 and 15 of the first cycle, then 250 mg/m² on Day 15 of subsequent cycles
Safety and Potential Side Effects
As with all cancer treatments, IMIFOPLATIN may cause side effects. The clinical trial is carefully monitoring patients for any adverse reactions. While specific side effects are not listed in the provided information, patients should be aware that platinum-based therapies can sometimes cause: Nausea and vomiting Fatigue Decreased blood cell counts Kidney problems
The trial is designed to find the dose that provides the best balance between effectiveness and tolerability.
Future Prospects
If the current Phase 1 trial shows promising results, IMIFOPLATIN may proceed to larger clinical trials. The goal is to determine if this new drug can provide a meaningful benefit to patients with advanced prostate cancer who have limited treatment options. However, it's important to note that many drugs in early-stage trials do not ultimately receive approval, and more research is needed to fully understand the potential of IMIFOPLATIN.